Replimune Group enters its August 18 earnings print with the sharpest bull-bear split in months — short sellers rebuilding aggressively while the analyst community upgrades in near-unison.
Short interest has become the defining tension on the stock. It jumped 37% in a single week to 32.4% of the free float, reaching 25.4 million shares borrowed. That build happened into a stock that has already rallied 52% over the past month to $14.97 — short sellers are leaning against the momentum, not chasing a falling name. The lending market, however, tells a different story about urgency. Availability has loosened dramatically, nearly doubling week-on-week to 1,227% — roughly twelve shares available for every one borrowed. Borrowing costs have fallen 25% over the past month to less than 0.7%. The shorts are crowding in on conviction, not because the borrow is scarce or the squeeze mechanics are tightening. The ORTEX short score of 55.5 sits elevated but well short of extreme territory.
Options positioning has modestly shifted toward caution over the past two weeks, though not dramatically. The put/call ratio is running at 0.86, just above its 20-day average of 0.82 — a modest half-standard-deviation lean toward protection. Notably, the PCR hit its 52-week high of 1.01 on August 7, the same day analysts were upgrading. That spike has since faded, suggesting the initial defensive reaction to the earnings approach has partially unwound rather than intensified.
The Street has moved decisively bullish. Three upgrades landed within days of each other — JP Morgan maintained Overweight and raised its target to $20 on August 7; Wedbush upgraded to Outperform and lifted its target from $12 to $19 the same day; Leerink Partners upgraded to Outperform with a $17 target on August 4. All five covering analysts now carry buy-equivalent ratings, with a consensus target of $19.33 — roughly 29% above Friday's close. The bull case centres on Replimune's RPx oncolytic immunotherapy platform and a fresh FDA review team for the RP1 BLA resubmission. Bears point to an interim OS readout for the IGNYTE-3 study not arriving until 2027, leaving the cash runway and trial funding as near-term overhangs. The company's EPS momentum ranks in the 89th percentile on a 30-day basis — a high score for a pre-profit biotech that reflects improving estimates rather than actual earnings.
Institutional ownership adds an interesting wrinkle. Montanova Capital filed a new position of 5.6 million shares as recently as July 30. BlackRock added 2.7 million shares in July. Goldman Sachs built a position of over 2 million shares through June. That institutional accumulation runs parallel to the analyst upgrades — but also parallel to the short build, which means the stock is being contested at both ends simultaneously. The CEO and CFO both sold shares on August 10 at $12.97, modest in size and low in trade significance, consistent with routine plan-based selling rather than a directional signal.
Two recent earnings prints offer thin but relevant context. The August 6 announcement produced a 1.9% next-day gain and a 28% five-day gain — a strong delayed reaction. The June 4 print saw the stock fall 5% the next day and 14% over the following week. The August 18 release is therefore less about the headline numbers and more about any update on FDA dialogue, trial design, and cash runway guidance, with the subsequent five-day window historically more informative than the immediate move.
See the live data behind this article on ORTEX.
Open REPL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
